UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549
--------------------------------------------------------------------------------

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


Date of Report (Date of earliest event reported):      December 15, 2003
                                                      --------------------------


                         PROVECTUS PHARMACEUTICALS, INC.
               (Exact Name of Registrant as Specified in Charter)


       Nevada                          0-9410                   90-0031917
--------------------------------------------------------------------------------
(State or Other Jurisdiction of      (Commission             (I.R.S. Employer
 Incorporation or Organization)      File Number)         Identification Number)

 7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee          37931
--------------------------------------------------------------------------------
       (Address of Principal Executive Offices)               (Zip Code)

Registrant's telephone number, including area code:    865/769-4011
                                                      --------------------------

--------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)





<PAGE>



Item 5.  Other Events.

     On December 15,  2003,  Provectus  Pharmaceuticals,  Inc.  (the  "Company")
announced  that it is  offering  for sale up to  approximately  $1 million  U.S.
dollars of its  restricted  common  stock.  If  successful,  net proceeds to the
Company are expected to be approximately  $400,000 to $600,000 U.S. dollars. The
transaction  is a  Regulation  S  offering  to foreign  investors  as defined by
Regulation S of the Securities Act of 1933, as amended (the  "Securities  Act").
The restricted shares cannot be traded for 12 months. After the first 12 months,
sale of the shares are subject to restrictions  under Rule 144 for an additional
year. The Company has engaged a placement agent to assist it in the offering.

     Neither the press  release nor this Current  Report on Form 8-K is an offer
to sell or the  solicitation  of an  offer  to buy the  common  stock  discussed
herein.  The common stock being issued in this offering has not been  registered
under the  Securities  Act and may not be offered  or sold in the United  States
except  pursuant  to  an  effective  registration  statement  or  an  applicable
exemption from the registration  requirements of the Securities Act. The Company
has not agreed to file a registration  statement  covering the offer and sale of
the shares.

     The Company issued a press release which is attached hereto as Exhibit 99.1
and incorporate herein by reference.


Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.

(c)  Exhibits.

     Exhibits required by Item 601 of Regulation S-B are incorporated  herein by
reference and are listed on the attached Exhibit Index, which begins on page X-1
of this Current Report on Form 8-K.





<PAGE>




                                   Signatures

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                      Provectus Pharmaceuticals, Inc.


Dated:   December 15, 2003            By:/s/ H. Craig Dees
                                      ------------------------------------------
                                      H. Craig Dees
                                      Chief Executive Officer

<PAGE>


                                  Exhibit Index

 Exhibit No.                      Description
--------------                    -----------

99.1          Press Release of Provectus Pharmaceuticals, Inc.
[{"type": "8-K", "sequence": "1", "filename": "pvct8k121503.txt", "description": "CURRENT REPORT FORM 8-K", "secsgml_size_bytes": 4083}]
{"company-data": {"conformed-name": "PROVECTUS PHARMACEUTICALS INC", "cik": "0000315545", "assigned-sic": "2834", "irs-number": "900031917", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-09410", "film-number": "031053970"}, "business-address": {"street1": "7327 OAK RIDGE HWY", "street2": "SUITE B", "city": "KNOXVILLE", "state": "TN", "zip": "37931", "phone": "865-769-4011"}, "mail-address": {"street1": "7327 OAK RIDGE HWY", "street2": "SUITE B", "city": "KNOXVILLE", "state": "TN", "zip": "37931"}, "former-company": [{"former-conformed-name": "ZAMAGE DIGITAL IMAGING INC", "date-changed": "20011126"}, {"former-conformed-name": "SPM GROUP INC", "date-changed": "19920703"}]}
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549
--------------------------------------------------------------------------------

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):      December 15, 2003
                                                      --------------------------

                         PROVECTUS PHARMACEUTICALS, INC.
               (Exact Name of Registrant as Specified in Charter)

       Nevada                          0-9410                   90-0031917
--------------------------------------------------------------------------------
(State or Other Jurisdiction of      (Commission             (I.R.S. Employer
 Incorporation or Organization)      File Number)         Identification Number)

 7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee          37931
--------------------------------------------------------------------------------
       (Address of Principal Executive Offices)               (Zip Code)

Registrant's telephone number, including area code:    865/769-4011
                                                      --------------------------

--------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)
Item 5.  Other Events.

     On December 15,  2003,  Provectus  Pharmaceuticals,  Inc.  (the  "Company")
announced  that it is  offering  for sale up to  approximately  $1 million  U.S.
dollars of its  restricted  common  stock.  If  successful,  net proceeds to the
Company are expected to be approximately  $400,000 to $600,000 U.S. dollars. The
transaction  is a  Regulation  S  offering  to foreign  investors  as defined by
Regulation S of the Securities Act of 1933, as amended (the  "Securities  Act").
The restricted shares cannot be traded for 12 months. After the first 12 months,
sale of the shares are subject to restrictions  under Rule 144 for an additional
year. The Company has engaged a placement agent to assist it in the offering.

     Neither the press  release nor this Current  Report on Form 8-K is an offer
to sell or the  solicitation  of an  offer  to buy the  common  stock  discussed
herein.  The common stock being issued in this offering has not been  registered
under the  Securities  Act and may not be offered  or sold in the United  States
except  pursuant  to  an  effective  registration  statement  or  an  applicable
exemption from the registration  requirements of the Securities Act. The Company
has not agreed to file a registration  statement  covering the offer and sale of
the shares.

     The Company issued a press release which is attached hereto as Exhibit 99.1
and incorporate herein by reference.

Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.

(c)  Exhibits.

     Exhibits required by Item 601 of Regulation S-B are incorporated  herein by
reference and are listed on the attached Exhibit Index, which begins on page X-1
of this Current Report on Form 8-K.
Signatures

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                      Provectus Pharmaceuticals, Inc.

Dated:   December 15, 2003            By:/s/ H. Craig Dees
                                      ------------------------------------------
                                      H. Craig Dees
                                      Chief Executive Officer
Exhibit Index

 Exhibit No.                      Description
--------------                    -----------

99.1          Press Release of Provectus Pharmaceuticals, Inc.